CORRECTION: AstraZeneca Q2 Adj. EPS $1.98 Inline, Adj. EPADS $0.99, Sales $12.98B Beat $12.60B Estimate
CORRECTION: AstraZeneca Q2 Adj. EPS $1.98 Inline, Adj. EPADS $0.99, Sales $12.98B Beat $12.60B Estimate
AstraZeneca (NASDAQ:AZN) reported quarterly adjsuted earnings of $0.99 per share which missed the analyst consensus estimate of $1.20 by 17.5 percent. This is a 7.91 percent decrease over earnings of $1.07 per share from
阿斯利康（納斯達克股票代碼：AZN）公佈的季度調整後每股收益爲0.99美元，比分析師普遍預期的1.20美元低17.5％。這比每股收益1.07美元下降了7.91％
AstraZeneca (NASDAQ:AZN) reported quarterly adjsuted earnings of $0.99 per share which missed the analyst consensus estimate of $1.20 by 17.5 percent. This is a 7.91 percent decrease over earnings of $1.07 per share from the same period last year. The company reported quarterly sales of $12.98 billion which beat the analyst consensus estimate of $12.75 billion by 1.83 percent. This is a 13.73 percent increase over sales of $11.42 billion the same period last year.
阿斯利康（納斯達克股票代碼：AZN）公佈的季度調整後每股收益爲0.99美元，比分析師普遍預期的1.20美元低17.5％。與去年同期的每股收益1.07美元相比，下降了7.91％。該公司公佈的季度銷售額爲129.8億美元，比分析師共識估計的127.5億美元高出1.83％。這比去年同期的114.2億美元銷售額增長了13.73％。